ARGX
NASDAQargenx SE
Price$882.63-10.00 (-1.12%)
01:30 PM07:45 PM
News · 26 weeks40-50%
2025-12-142026-06-07
Mix2090d
- Other9(45%)
- SEC Filings7(35%)
- Leadership2(10%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following switch to biweekly dosingCross-indication analysis of efgartigimod data across rheumatology studies underscores consistent safety profile in large patient population June 3, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimo
- PRargenx to Host Myositis R&D Webinar on June 23, 2026May 28, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis" on Tuesday, June 23, 2026, at 2:00pm ET. The second webinar in the Company's ‘mini' series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease
- PRargenx to Present at Upcoming Investor ConferencesMay 27, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June: William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.Goldman Sachs 47th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the web
- PRThe Biology Came First.Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMGVYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegativePatients treated with VYVGART in the ADAPT SERON study experienced rapid, significant and sustained symptom improvements that continued with ongoing treatment Approval advances argenx's commitment to address the unique needs of every MG patient, delivering the broadest MG label to date May 8, 2026, 5:20 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Reports First Quarter 2026 Financial Results and Provides Business Update$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative ("seronegative") gMG PDUFA is May 10, 2026 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 7, 2026 7:00AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2026 results and provided a business update. "argenx continues to deliver meaningful impact for patients, reflected by our 17th consecutive quarter of VYVGART growth," said Karen Massey, Chief Executive Officer of argen
- PRargenx to Present at BofA Securities 2026 Health Care ConferenceMay 6, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committed to improving the lives of people suff
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive OfficerLeadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors' appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. "Karen has earned the full confidence of the Board of Directors and our shareholders," said Tim Van Hauwermeiren, Chair of the Board of Directors. "She is a proven leader who has played a central role in shaping argenx's ex
- SECAmendment: SEC Form SCHEDULE 13G/A filed by argenx SESCHEDULE 13G/A - ARGENX SE (0001697862) (Subject)
- PRargenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026April 30, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium 32 800 50 201France
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDPADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx announces Annual General Meeting of Shareholders on May 6, 2026March 20, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting a
- SECSEC Form 20-F filed by argenx SE20-F - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- ANALYSTargenx upgraded by Deutsche BankDeutsche Bank upgraded argenx from Hold to Buy
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelinePositive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
ARGX FAQ
7 questionsWhat does argenx SE do?
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with...Where does ARGX stock trade?
argenx SE (ARGX) is listed on NASDAQ.What sector and industry is ARGX in?
argenx SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did argenx SE go public?
argenx SE (ARGX) completed its IPO in 2017.What are analysts saying about ARGX?
argenx SE has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy on 2026-03-10.What companies are similar to ARGX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), SGEN (Seagen Inc.). Compare ARGX side-by-side with any of them on Quantisnow.How can I track ARGX on Quantisnow?
Quantisnow aggregates argenx SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARGX to receive live email and push alerts on every new disclosure.